A retrospective study on the efficacy and safety of donafenib combined with transarterial chemoembolization (TACE) and with/without immunotherapy in intermediate-advanced hepatocellular carcinoma (HCC).

被引：0
|
作者：
Chen, Cong
Fu, Shouzhong
Zhao, Suming
Yuan, Hongxin
Dai, Feng
Gu, Weiwei
Gu, Zhuxin
Shi, Rongfeng
Yang, Xiaohu
Lu, Xiaohua
Jia, Pengfei
Si, Luyi
Zhao, Hui
机构：
[1] Affiliated Hosp Nantong Univ, Nantong, Peoples R China
[2] Nantong Univ, Nantong Peoples Hosp 3, Nantong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16171
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of donafenib combined with transarterial chemoembolization (TACE) for treating intermediate/advanced-stage hepatocellular carcinoma (HCC): A retrospective real-world study
    Wei, Ning
    Lu, Dong
    Xiao, Jingkun
    Zhou, Chunze
    Zhang, Xingming
    Xu, Shaobao
    Zhang, Zhengfeng
    Cheng, Delei
    Shi, Changsheng
    Liu, Kaicai
    Gao, Zonggen
    Zhu, Yijiang
    Chu, Senlin
    Yin, Liang
    Su, Mingxue
    Lv, Weifu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Efficacy and safety of transarterial chemoembolization (TACE) in combination with tislelizumab and TKIs versus TACE for the treatment of Intermediate and advanced HCC: A retrospective cohort study
    Han, Y.
    Tang, S.
    Gao, Y.
    Yan, X.
    Zhi, W.
    Gong, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S1494 - S1494
  • [3] Original Comparison of efficacy and safety between transarterial chemoembolization (TACE) combined with lenvatinib versus TACE combined with sorafenib in the treatment of intermediate and advanced hepatocellular carcinoma
    Xu, Rui
    Ji, Xuebing
    Pei, Xiaohong
    Yu, Yongqiang
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2023, 15 (02): : 1117 - 1128
  • [4] Investigation of the Difference of Efficacy and Safety of TACE Combined with Sintilimab and Bevacizumab versus TACE Combined with Donafenib in Patients with Intermediate or Advanced Hepatocellular Carcinoma
    Sun, Yanjun
    Wang, Xing
    Ling, Changchun
    Yu, Yong
    Jia, Pengfei
    Lu, Xiaohua
    Zhao, Hui
    Gu, Zhuxin
    WIENER KLINISCHE WOCHENSCHRIFT, 2024, 136 : S412 - S412
  • [5] Transarterial chemoembolization combined with lenvatinib and sintilimab vs lenvatinib alone in intermediate-advanced hepatocellular carcinoma
    Wu, Fei-Da
    Zhou, Hai-Feng
    Yang, Wei
    Zhu, Di
    Wu, Bi-Fei
    Shi, Hai-Bin
    Liu, Sheng
    Zhou, Wei-Zhong
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2025, 17 (01)
  • [6] Combined Transarterial Chemoembolization (TACE) and Percutaneous Local Ablation Therapy for Advanced Hepatocellular Carcinoma (HCC)
    Kirikoshi, Hiroyuki
    Saito, Satoru
    Yoneda, Masato
    Fujita, Koji
    Mawatari, Hironori
    Nozaki, Yuichi
    Suzuki, Kaori
    Endo, Hiroki
    Takahashi, Hirokazu
    Abe, Yasunobu
    Inamori, Masahiko
    Kobayashi, Noritoshi
    Kubota, Kensuke
    Nakajima, Atsushi
    GASTROENTEROLOGY, 2010, 138 (05) : S809 - S810
  • [7] Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective study
    Qiu, Zhiyu
    Shen, Lujun
    Jiang, Yiquan
    Qiu, Jiliang
    Xu, Zining
    Shi, Mengting
    Yu, Zhentao
    Ma, Yanping
    He, Wei
    Zheng, Yun
    Li, Binkui
    Wang, Guoying
    Yuan, Yunfei
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (04)
  • [8] Transarterial chemoembolization combined donafenib with/without PD-1 for unresectable HCC in a multicenter retrospective study
    Li, Hao
    Wang, Jiacheng
    Zhang, Guokun
    Kuang, Donglin
    Li, Yanliang
    He, Xiang
    Xing, Cheng
    Wang, Yong
    Shi, Ming
    Han, Xinwei
    Ren, Jianzhuang
    Duan, Xuhua
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [9] Efficacy and Safety of Transarterial Chemoembolization Combined With Anlotinib for Unresectable Hepatocellular Carcinoma: A Retrospective Study
    Guo, Wenbo
    Chen, Song
    Wu, Zhiqiang
    Zhuang, Wenquan
    Yang, Jianyong
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2020, 19
  • [10] Treatment with camrelizumab plus tyrosine kinase inhibitors with or without TACE for intermediate-advanced hepatocellular carcinoma: a clinical efficacy and safety study
    Yin, Yaolin
    Li, Yonghe
    Xiong, Yongfu
    Xian, Yin
    Meng, Chun
    He, Kun
    He, Yi
    Li, Jingdong
    ONCOLOGIE, 2023, 25 (03) : 257 - 267
12345